天津医药

• 论著 • 上一篇    下一篇

冠脉造影术前强化瑞舒伐他汀治疗对循环内皮祖细胞的影响

孙富强1,高明东2,马玉东3,刘寅4,孙根义4   

  1. 1. 天津医科大学研究生院
    2. 天津市胸科医院
    3. 天津医科大学
    4. 天津市胸科医院心内科
  • 收稿日期:2012-08-28 修回日期:2012-10-16 出版日期:2013-06-15 发布日期:2013-06-15
  • 通讯作者: 刘寅

The Influence of High-Dose Rosuvastatin on Circulating Endothelial Progenitor Cells

SUN Fuqiang 1,GAO Mingdong 2,MA Yudong 1,LIU Yin 2,SUN Genyi 2   

  1. 1. Tianjin Medical University
    2. Tianjin Chest Hospital
  • Received:2012-08-28 Revised:2012-10-16 Published:2013-06-15 Online:2013-06-15
  • Contact: LIU Yin

PDF (PC)

2558

摘要： 【摘要】目的  观察冠脉造影术前24 h不同剂量瑞舒伐他汀治疗对循环内皮祖细胞数量的影响，探究冠脉介入术前强化他汀治疗获益的机制。方法 将拟行冠脉造影检查的42例患者随机分为2组：10 mg组20例，20 mg组22例。2组均顿服瑞舒伐他汀治疗。治疗前及治疗24 h后（冠脉造影前），流式细胞仪检测患者循环内皮祖细胞数量。根据冠脉造影结果，再将上述2组各分为冠心病组和冠脉造影阴性组2个亚组。结果  治疗后，2组循环内皮祖细胞数量与治疗前相比（10 mg组：49.95±24.57 vs 42.95±21.18; 20 mg组：57.68±17.62 vs 48.32±22.47）差异无统计学意义（P >0.05）。2组循环内皮祖细胞数量变化量（7.00±18.94 vs 9.36±22.44）比较差异无统计学意义（P > 0.05）。亚组分析表明，冠心病组服用20 mg瑞舒伐他汀24 h后循环内皮祖细胞数量较治疗前增加（56.92±12.27 vs 42.08±21.27），差异有统计学意义（P <0.05）。结论  冠心病患者介入术前24 h应用20 mg瑞舒伐他汀可以提高循环内皮祖细胞数量，可能是冠脉介入术前强化他汀治疗获益的机制之一。

关键词: 冠状动脉疾病, 血管成形术, 经腔, 经皮冠状动脉, 内皮, 血管, 内皮细胞, 流式细胞术

Abstract: [Abstract]   Objective  To observe different doses of rosuvastatin on circulating endothelial progenitor cells at 24 hours before coronary angiography (CAG), and to explore the mechanism of therapeutic benefit of high-dose statin before percutaneous coronary intervention (PCI). Methods   Forty-two cases who were to undergo CAG were randomly divided into two groups: 10 mg group (n=20) and 20 mg group (n=22). All subjects took rosuvastatin at a draught. Before treatment and 24 hours after treatment (before CAG), flow cytometry was used to test the number of circulating endothelial progenitor cells(CEPCs). According to the results of CAG, the two groups were respectively divided into two subgroups:coronary artery disease (CHD) group and CAG negative group. Results  After treatment, the numbers of CEPCs in two groups were not significantly changed (10 mg group：49.95±24.57 vs 42.95±21.18, P > 0.05; 20 mg group：57.68±17.62 vs 48.32±22.47, P > 0.05).There was no significant difference in the changed number of CEPCs between 10 mg group and 20 mg group (7.00±18.94 vs 9.36±22.44, P > 0.05). The subgroup analysis showed that the number of CEPCs was significantly increased in CHD group than before treatment with 20 mg rosuvastatin（56.92±12.27 vs 42.08±21.27 , P < 0.05). Conclusion   Taking 20 mg rosuvastatin in patients with CHD at 24 h before PCI increases the number of CEPCs, which may be one of the mechanisms of benefit of high-dose statin therapy before PCI.

Key words: Coronary diseases, angioplasty, transluminal, percutaneous coronary, endothelial cells, flow cytometry, Rosuvastatin, 流式细胞术